News

Click here to answer this week's skin cancer poll.

Zakiya Pressley Rice, MD, took a deep dive into how atopic dermatitis severity and increased rates of grade school absenteeism affect patients with skin of color during a recent Masterclasses in Dermatology meeting.

Understanding these relationships is crucial for developing effective clinical management strategies for patients with AD, according to a recent literature review.

2023 was full of advancements in both medical and cosmetic dermatology, and 2024 is shaping up to be just as exciting.

Ahead of 2024, Dermatology Times wants to know what conferences and meetings you plan to attend in early 2024. Share your thoughts with us by December 10.

A review examined the treatment landscape of BCC, particularly in the realm of photodynamic therapy.

With artificial intelligence taking front and center in many aspects of our lives, will it be more prevalent in the dermatology practice than it is now?

Click here to answer this week's acne poll.

Keep up with the latest headlines in dermatology from the past week, including the launch of a free dermatology and wound care clinic, a glimpse into the future of cosmetic dermatology, and more.

ICYMI, this week we had articles about the FDA granting priority review of Abeona's pz-cel BLA for recessive DEB, end-of-the-month highlights from the November issue and supplement of Dermatology Times, the FDA accepting Arcutis' sNDA of roflumilast cream 0.15% for AD, and more.

Investigators also developed a MELASQoL model using 4 predictors of quality of life impacts in patients with melasma.

This World Aids Day, review the common dermatologic manifestations of AIDS and HIV infection.

The addition of bemcentinib to the standard-of-care therapies of pembrolizumab or dabrafenib plus trametinib was well tolerated in patients with metastatic melanoma; however, it did not lead to improvements in overall response rate, progression-free survival, or overall survival vs SOC alone.

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

The technology combines the irradiation of two wavelengths at 10,600 nm and 1540 nm.

The US license period will start on February 22, 2025.

Learn more about the in-depth topics covered in the November 2023 Frontline Forum corticosteroid-responsive dermatoses supplement of Dermatology Times.

Learn more about the in-depth topics covered in the November 2023 print issue of Dermatology Times.

With greater understanding of this rare pathology and its signs and symptoms, review authors believe this understanding could prompt early and necessary intervention.

Each of 3 patients treated with cemiplimab achieved a near complete response.

A recent study linked alopecia areata and the presence of cochlear dysfunction in some patients.

The sNDA is supported by positive data from the phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials.

Depression, functional impairment, and worsened quality of life are related in patients with psoriatic disease, according to a recent study.

Identifying social determinants in TEM is crucial to eliminating disparities in care, study authors wrote.

A phase 1 study found that RPT193 monotherapy led to greater improvements in clinical efficacy than treatment with a placebo.

As more dermatology clinicians find themselves increasingly exhausted, being in a hurry can lead to legal repercussions.

The FDA’s PDUFA target date is May 25, 2024.

Ted Lain, MD, MBA, moderated a discussion to share strategies to optimize treatment sequencing, reevaluate long-term management, understand barriers to novel therapies, promote prior authorization integration, and diversify treatment areas.

This article compares physicians in general to average US investors in several key areas and examines how these factors affect a dermatologist’s approach to investing and wealth management.

In this week’s Pointers With Portela, the 208SkinDoc reviews on his podcast why it's dangerous to have moles lasered off before taking a biopsy.